SCHEMBL3016729

SCHEMBL3016729

COc1ccc(S(=O)(=O)C2CCN(c3nc(Cc4ccc(OC)c(OC)c4)cs3)CC2)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 2/20 0.41
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
F2RL3 Q96RI0 6/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NPC1 O15118 2/20 0.37
REV1 Q9UBZ9 1/20 0.37
CYP19A1 P11511 1/20 0.36
GPR6 P46095 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003017 0.94 ALDH1A1 (0.44) ALDH1A1KDM4ELMNARAB9ASMN1; SMN2
SCHEMBL3018545 0.94 ALDH1A1 (0.41) ALDH1A1KDM4ELMNARAB9ASMN1; SMN2
SCHEMBL3002013 0.91 MAPT (0.37) ALDH1A1LMNARAB9ASMN1; SMN2HPGD
SCHEMBL3014322 0.91 MAPT (0.38) ALDH1A1KDM4ELMNARAB9ASMN1; SMN2
SCHEMBL3006114 0.91 MAPT (0.40) ALDH1A1LMNARAB9ASMN1; SMN2HPGD
SCHEMBL3011687 0.91 MAPT (0.38) ALDH1A1LMNARAB9ASMN1; SMN2HPGD
SCHEMBL3015289 0.91 MAPT (0.41) ALDH1A1LMNARAB9ASMN1; SMN2HPGD
SCHEMBL3009170 0.91 MAPT (0.39) ALDH1A1LMNARAB9ASMN1; SMN2HPGD
SCHEMBL3012771 0.91 ERBB2 (0.38) ALDH1A1LMNARAB9ASMN1; SMN2HPGD
SCHEMBL3019179 0.91 MAPT (0.40) ALDH1A1LMNARAB9ASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885KDM4E 4398/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.